Title |
Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
|
---|---|
Published in |
Open Access Rheumatology : Research and Reviews , July 2018
|
DOI | 10.2147/oarrr.s169152 |
Pubmed ID | |
Authors |
James R O’Dell, Stanley B Cohen, J Carter Thorne, Joel Kremer |
Abstract |
The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). MTX is underused in the treatment of RA in the USA. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 1 | 50% |
Germany | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 36% |
Other | 3 | 27% |
Student > Master | 1 | 9% |
Professor | 1 | 9% |
Professor > Associate Professor | 1 | 9% |
Other | 1 | 9% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 64% |
Biochemistry, Genetics and Molecular Biology | 2 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Unknown | 1 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2018.
All research outputs
#19,951,180
of 25,385,509 outputs
Outputs from Open Access Rheumatology : Research and Reviews
#143
of 192 outputs
Outputs of similar age
#250,846
of 341,606 outputs
Outputs of similar age from Open Access Rheumatology : Research and Reviews
#4
of 5 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 192 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,606 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.